MedElevator
Войти в исследования Headache · 2025
First successful protocol for desensitization to eptinezumab.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gerard Benoit, Praudel Hubert, Lanteri-Minet Michel, Van Obberghen Elise, Rocher-Moreau Fanny, Rousset Johanna, Jacquier Ulysse, Leroy Sylvie, Delin Margot
Аннотация
BACKGROUND: Eptinezumab is an anti-calcitonin gene-related peptide monoclonal antibody used for migraine prevention. During clinical trials, hypersensitivity to eptinezumab was described without a clear underlying mechanism. To determine if the reaction was immunoglobulin E-mediated, the team of Nice University Hospital (Nice, France) performed the eptinzeumab skin tests. A 10-step desensitization protocol has been proposed to manage these reactions.
FINDINGS: Two patients presenting with immediate hypersensitivity reactions underwent the eptinezumab skin test. Neither skin test was positive, suggesting a non-immunoglobulin E-mediated mechanism. The patients then completed the desensitization protocol successfully.
CONCLUSION: This hospital-based 10-step desensitization protocol appears safe and effective.
FINDINGS: Two patients presenting with immediate hypersensitivity reactions underwent the eptinezumab skin test. Neither skin test was positive, suggesting a non-immunoglobulin E-mediated mechanism. The patients then completed the desensitization protocol successfully.
CONCLUSION: This hospital-based 10-step desensitization protocol appears safe and effective.